Basic Information
Orgovyx
Regulatory Information
EMEA/H/C/005353
Authorised
April 29, 2022
February 24, 2022
11
November 21, 2024
Company Information
Spain
Edificio Este Planta 6a World Trade Center Moll De Barcelona S/n 08039 Barcelona
ACCORD HEALTHCARE SL
Drug Classification
Additional Monitoring
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.
Overview Summary
Orgovyx is a medicine used to treat advanced cancer of the prostate (a gland of the male reproductive system) in adult patients when the cancer is ‘hormone-sensitive’, which means that it responds to treatments that reduce the levels of testosterone (the male sex hormone). Orgovyx contains the active substance relugolix.